Testing microRNA for pancreatic cancer diagnosis and treatment response
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study looks at tiny molecules in your body (microRNA) to help doctors better diagnose pancreatic cancer, predict how it may progress, and understand how it responds to treatment. It may help guide more personalized care in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed biopsy showing pancreatic adenocarcinoma (a specific type of pancreatic cancer).
- Your cancer started as inoperable, meaning it cannot be removed with surgery at first (either locally advanced or metastatic).
- Your cancer can be measured on scans (there is something visible the study can track).
- Your day-to-day functioning is limited but not severely (ECOG 2 or less).
- You can provide the required samples/specimens and information for the study.
- You agree to join by signing an informed consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses advanced genetic testing on your tumor sample and lab-grown tumor 'organoids' to help pick treatments that may work better for your metastatic pancreatic cancer. The goal is to find a more personalized treatment plan for you.
This study looks at blood tests to find markers that may help detect and monitor pancreatic cancer. It compares people with pancreatic cancer to those with benign pancreatic conditions and healthy volunteers.
This study looks at how tiny particles in blood (“exosomes”) carry signals between cells in people having pancreatic surgery. The goal is to understand these signals in different pancreatic conditions and treatment situations, which may help future care.
This study uses a special blood test to look for tiny amounts of cancer DNA after your pancreatic cancer surgery. It may help doctors see early if the cancer is coming back, so they can act sooner.
This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
Hear when a new Pancreatic Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.